- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis? ; volume:5 ; number:1 ; day:19 ; month:12 ; year:2017 ; pages:1-3 ; date:12.2017
Journal for ImmunoTherapy of Cancer ; 5, Heft 1 (19.12.2017), 1-3, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Sun, Roger
- Beteiligte Personen und Organisationen
-
Danlos, Francois-Xavier
Ammari, Samy
Louvel, Guillaume
Dhermain, Frédéric
Champiat, Stéphane
Lambotte, Olivier
Deutsch, Eric
SpringerLink (Online service)
- DOI
-
10.1186/s40425-017-0304-8
- URN
-
urn:nbn:de:1111-2018013112755
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 08:56 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sun, Roger
- Danlos, Francois-Xavier
- Ammari, Samy
- Louvel, Guillaume
- Dhermain, Frédéric
- Champiat, Stéphane
- Lambotte, Olivier
- Deutsch, Eric
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie